- Home
- AMIX vs DWTX Comparison
AMIX vs DWTX Comparison
Compare AMIX & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- DWTX
- Stock Information
- Founded
- AMIX 2014
- DWTX 2012
- Country
- AMIX United States
- DWTX United States
- Employees
- AMIX N/A
- DWTX N/A
- Industry
- AMIX
- DWTX
- Sector
- AMIX
- DWTX
- Exchange
- AMIX NYSE
- DWTX NYSE
- Market Cap
- AMIX 5.5M
- DWTX 5.9M
- IPO Year
- AMIX N/A
- DWTX N/A
- Fundamental
- Price
- AMIX $1.97
- DWTX $5.66
- Analyst Decision
- AMIX
- DWTX Strong Buy
- Analyst Count
- AMIX 0
- DWTX 1
- Target Price
- AMIX N/A
- DWTX $10.00
- AVG Volume (30 Days)
- AMIX 13.5K
- DWTX 2.4M
- Earning Date
- AMIX 05-30-2025
- DWTX 05-14-2025
- Dividend Yield
- AMIX N/A
- DWTX N/A
- EPS Growth
- AMIX N/A
- DWTX N/A
- EPS
- AMIX N/A
- DWTX N/A
- Revenue
- AMIX N/A
- DWTX N/A
- Revenue This Year
- AMIX N/A
- DWTX N/A
- Revenue Next Year
- AMIX N/A
- DWTX N/A
- P/E Ratio
- AMIX N/A
- DWTX N/A
- Revenue Growth
- AMIX N/A
- DWTX N/A
- 52 Week Low
- AMIX $1.52
- DWTX $1.62
- 52 Week High
- AMIX $75.80
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- AMIX 53.21
- DWTX N/A
- Support Level
- AMIX $1.61
- DWTX N/A
- Resistance Level
- AMIX $2.06
- DWTX N/A
- Average True Range (ATR)
- AMIX 0.11
- DWTX 0.00
- MACD
- AMIX 0.07
- DWTX 0.00
- Stochastic Oscillator
- AMIX 82.59
- DWTX 0.00
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.